More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.63B
EPS
-0.48
P/E ratio
--
Price to sales
61.41
Dividend yield
--
Beta
1.596249
Previous close
$11.49
Today's open
$11.23
Day's range
$11.03 - $11.44
52 week range
$2.75 - $15.02
CEO
Carl Hansen
Employees
562
Headquarters
Vancouver, BC
Exchange
Nasdaq Global Select
Shares outstanding
326617896
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript
AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • 13 hours ago

AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of 2027, Chief Executive Carl Hansen said at the Jefferies 2026 Global Healthcare Conference in London.
MarketBeat • Nov 16, 2026

AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division All right.
Seeking Alpha • Nov 13, 2026

AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected efficacy results, CEO Carl Hansen said at a Stifel event.
MarketBeat • Nov 12, 2026

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Zacks Investment Research • Nov 12, 2026

What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further development of a separate antibody candidate for now.
MarketBeat • Nov 10, 2026

AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

AbCellera Reports Q3 2026 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.
Business Wire • Nov 9, 2026

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.
Zacks Investment Research • Nov 9, 2026

AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026.
Business Wire • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell AbCellera Biologics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.